Determination of fentanyl, metabolite and analogs in urine by GC/MS

Journal of Applied Toxicology

Volumn 31, Issue 7, 2011, Pages 649-654

  Strano Rossi, Sabina ^a   Álvarez, Iván ^b   Tabernero, María Jesús ^b   Cabarcos, Pamela ^b   Fernández, Purificación ^b   Bermejo, Ana María ^b  

^a Antidoping Laboratory   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Doping analysis; Fentanyl and analogs; Forensic toxicology; GC MS; Urine analysis

Indexed keywords

ALFENTANIL; FENTANYL; SUFENTANIL;

ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG FATALITY; DRUG OVERDOSE; DRUG URINE LEVEL; HUMAN; LIQUID LIQUID EXTRACTION; METABOLITE; PRIORITY JOURNAL; URINALYSIS;

ALFENTANIL; CALIBRATION; FENTANYL; FLUOROCARBONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; LIQUID-LIQUID EXTRACTION; REPRODUCIBILITY OF RESULTS; SUFENTANIL;

EID: 80055024333     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1613     Document Type: Article

References (22)

1. Bagheri H, Es-haghi A, Khalilian F, Rouini MR. 2007. Determination of fentanyl in human plasma by head-space solid-phase microextraction and gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 43: 1763-1768.
2. Denton JS, Donoghue ER, McReynolds J, Kalelkar MB. 2008. An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007. J. Forensic Sci. 53: 452-454.
3. Goldberger BA, Chronister CW, Merves ML. 2010. Quantitation of fentanyl in blood and urine using gas chromatography-mass spectrometry (GC-MS). Meth. Mol. Biol. 603: 245-252.
4. Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S. 1984. Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry. Anesthesiology 61: 73-77.
5. Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Szekely SM, Mather LE, Owen H, Cousins MJ. 1990. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 40: 21-28.
6. Gunnar T, Ariniemi K, Lillsunde P. 2005. Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry. J. Mass Spectrom. 40: 739-753.
7. Hammergren WR, Henderson GL. 1988. Analyzing normetabolites of the fentanyls by gas chromatography/electron capture detection. J. Anal. Toxicol. 12: 183-191.
8. Hull MJ, Juhascik M, Mazur F, Flomenbaum MA, Behonick GS. 2007. J. Forensic Sci. 52: 1383-1388.
9. Kuhlman JJ Jr, McCaulley R, Valouch TJ, Behonick GS. 2003. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J. Anal. Toxicol. 27: 499-504.
10. Lemmens H. 1995. Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin. Pharmacokinet. 29: 231-242.
11. Lilleng PK, Mehlum LI, Bachs L, Morild I. 2004. Deaths after intravenous misuse of transdermal fentanyl. J. Forensic Sci. 49: 1364-1366.
12. Mather LE. 1983. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 8: 422-446.
13. Paradis C, Dufresne C, Bolon M, Boulieu R. 2002. Solid-phase microextraction of human plasma samples for determination of sufentanil by gas chromatography-mass spectrometry. Ther. Drug Monit. 24: 768-774.
14. Poklis A, Backer R. 2004. Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. J. Anal. Toxicol. 28: 422-425.
15. Porreca F, Ossipov MH. 2009. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 10: 654-662.
16. Scholz J, Steinfath M, Schulz M. 1996. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin. Pharmacokinet. 31: 275-292.
17. Thompson JG, Baker AM, Bracey AH, Seningen J, Kloss JS, Strobl AQ, Apple FS. 2007. Fentanyl concentrations in 23 postmortem cases from the hennepin county medical examiner's office. J. Forensic Sci. 52: 978-981.
18. Valaer AK, Huber T, Andurkar SV, Clark CR, DeRuiter J. 1997. Development of a gas chromatographic-mass spectrometric drug screening method for the N-dealkylated metabolites of fentanyl, sufentanil, and alfentanil. J. Chromatogr. Sci. 35: 461-456.
19. Van Nimmen N, Poels K, Veulemans H. 2004. Highly sensitive gas chromatographic-mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfentanil and their major metabolites in urine of opioid exposed workers. J. Chromatogr. B 804: 375-387.
20. Wong SC, Curtis JA, Wingert WE. 2008. Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia Medical Examiner's Office. J. Forensic Sci. 53: 495-498.
21. World Antidoping Agency. 2010a. The World Anti-Doping Code. The 2010 Prohibited List International Standard. Available from: (accessed July 2010).
22. World Antidoping Agency. 2010b. Minimum Required Performance Levels for detection of Prohibited Substances. WADA Technical Document TD 2009MRPL. Available from: (accessed July 2010).